SecBot SecBot
6-K ·Filed May 13, 2026

BRSYF

Brainsway Ltd.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001171843-26-003345
Notable filing: 6-K
Actionable Insight ▲ Bullish

Strong Q1 beat across all metrics with reiterated guidance suggests accelerating momentum. Watch for FDA filing in Q2 2026 for PTSD indication, which could expand TAM. The $8.5 million in financial asset purchases (likely convertible loans) signals active capital deployment but also cash burn, monitor cash position in subsequent quarters.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.84
T+0 close · May 13, 2026 · via day close
Latest settled
−10.15%
T+60 · $15.13
Vs SPY
−14.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $16.84entry
  2. T+1 · 6mo ago 0.00%α −0.78% · $16.84
  3. T+5 · 6mo ago 0.00%α +1.16% · $16.84
  4. T+20 · 5mo ago 0.00%α +0.61% · $16.84
  5. T+60 · 3mo ago −10.15%α −14.59% · $15.13

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay reported Q1 2026 revenue of $15.5 million (up 35% YoY) and net income of $2.3 million (up >100% YoY), with Adjusted EBITDA more than doubling to $2.8 million. The company reiterated full-year 2026 guidance of $66-$68 million in revenue and $12-$14 million in Adjusted EBITDA, supported by record system shipments and expanding payer coverage.

Key Facts

  • Q1 2026 revenue of $15.5 million, up 35% from $11.5 million in Q1 2025
  • Net income of $2.3 million, up >100% from $1.1 million in Q1 2025
  • Adjusted EBITDA of $2.8 million, up 117% from $1.3 million in Q1 2025
  • Operating income of $2.0 million, up from $0.6 million in Q1 2025
  • Gross margin steady at 75%
  • Shipped 117 Deep TMS systems in Q1 2026, up 44% YoY; installed base ~1,820 systems
  • Remaining performance obligations of $75 million, up 25% YoY
  • Cash and equivalents of $58.6 million as of March 31, 2026
  • Reiterated FY2026 guidance: revenue $66-$68 million, operating income 13%-14% of revenue, Adjusted EBITDA $12-$14 million
  • Completed $6 million convertible loan to Neurolief and $1 million minority stake in BrainStim Health Inc.

Financial Impact

Revenue growth of 35% YoY to $15.5 million, net income more than doubled to $2.3 million, Adjusted EBITDA up 117% to $2.8 million

revenuenet incomeadjusted EBITDAoperating incomegross margin

Risk Factors

  • Cash and equivalents declined from $67.7 million to $58.6 million in Q1 2026, partly due to $8.5 million in financial asset purchases
  • Trade receivables increased to $7.5 million from $4.1 million, indicating potential collection risk
  • Ongoing patent litigation with Magnus Medical noted in prior 20-F filing
  • Reliance on single large customer as noted in prior annual report

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003345
Document: f6k_051226.htm0001171843-26-003345
Document: 0001171843-26-003345-index-headers.html0001171843-26-003345
Document: 0001171843-26-003345-index.html0001171843-26-003345
Document: 0001171843-26-003345.txt0001171843-26-003345

Track record

5 reports on BRSYF

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +24.28% at T+20 after the Apr 15, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Jun 9, 202622w ago 6-K Bullish 7/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.24% vs SPY
  2. May 18, 202626w ago 6-K Neutral 4/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −15.01% vs SPY
  3. May 13, 202626w ago 6-K Bullish 8/10 Viewing Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.59% vs SPY
  4. Apr 20, 202630w ago 20-F Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +4.76% vs SPY
  5. Apr 15, 202630w ago 6-K Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +3.52% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026